What is PCRX's market cap?

$1.45B, based on the Oct 14 close of $36.40.

What is PCRX's P/E ratio?

99.2× trailing-twelve-month earnings of $14.64M.

Does Pacira BioSciences pay a dividend?

No regular cash dividend has been paid in the last year.

How much of PCRX is sold short?

8.1M shares, 21.2% of float, as of Sep 30, 2026.

What sector is PCRX in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · PCRXHealthcarePharmaceuticals

Pacira BioSciences, Inc. Common Stock (PCRX)

$36.40+0.25%

Close Oct 14, 2026 · split-adjusted

Oct 14, 2026$36.40▲ 60.14% in range

Oct 14, 2025Low $19.16 · High $36.40Oct 14, 2026

What changed · written from our data

As of Oct 14, 2026

Pacira BioSciences closed at $36.40 on Oct 14, up 0.25% — matching its 52-week closing high. Volume of 2.3M shares was 1.00× its 20-day average (close to normal).

Split-adjusted performance: +51.2% over one month, +55.4% over six months, +63.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $192.40M, up 6.2% from a year earlier, with a net margin of 2.4%.

Short interest was 8.1M shares at the Sep 30 settlement, up 6.8% from the prior report (21.2% of float, 15.1 days to cover).

Market cap$1.45B39.9M shares

Revenue · quarter$192.4M+6.2% YoY

Diluted EPS$0.12—

P/E · TTM99.2×P/S 1.9×

Net margin2.4%Gross 77.0%

Dividend yieldNone

52-week range19.16 – 36.400.0% from high

Volume2.3M1.00× 20-day avg

Volatility · 60d82.8%Annualised

Short % of float21.2%15.1 days to cover

Net cash-$112.1MCash $251.0M

Next earnings—Not scheduled

Split-adjusted performance

1W +44.4%1M +51.2%3M +42.2%6M +55.4%YTD +40.6%1Y +63.5%3Y +20.3%5Y −25.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 421 companies (100 = best)

6-month momentum94

Revenue growth49

Net margin70

Value (low P/E)10

Size76

Industry medians: 6-month return −23.4%, revenue growth +6.4%, net margin −39.7%, P/E 15.4×.

Short interest

Details →

Shares short8.1M+6.8% vs prior

Days to cover15.1Settled Sep 30

% of float21.2%

Short vol. 10d58.5%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
PCRXPacira BioSciences	$36.40	+0.25%	+55.4%	+6.2%	2.4%	99.2	$1.45B
QUREuniQure	$20.97	−1.46%	+21.6%	+11.0%	−1387.8%	—	$1.45B	Compare
RAREUltragenyx Pharmaceutical	$14.90	−0.13%	−40.8%	+28.1%	−43.0%	—	$1.47B	Compare
STOKStoke Therapeutics	$23.26	+3.38%	−34.6%	−32.5%	−660.8%	—	$1.50B	Compare
ETONEton Pharmaceutcials	$52.88	−0.84%	+96.1%	+98.6%	30.8%	119.1	$1.51B	Compare
ANABAnaptysBio	$46.67	+2.37%	−31.3%	−8.0%	−206.9%	—	$1.40B	Compare
INVAInnoviva	$20.97	+1.11%	−12.3%	+19.3%	−69.8%	4.2	$1.51B	Compare
KLRAKailera Therapeutics	$10.74	−0.28%	—	—	—	—	$1.39B	Compare
PAHCPhibro Animal Health	$37.93	+3.04%	−31.0%	+4.8%	5.5%	15.4	$1.54B	Compare

News about Pacira BioSciences

All news →

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioZacks Investment Research · 6d ago▲ Positive Why Pacira BioSciences Skyrocketed TodayThe Motley Fool · Oct 8, 2026▲ Positive PCRX Expands Exparel Commercial Reach in Europe Through Molteni DealZacks Investment Research · Oct 6, 2026▲ Positive Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?Zacks Investment Research · Sep 3, 2026Neutral Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026GlobeNewswire Inc. · Jul 22, 2026▲ Positive

Quick answers

What does Pacira BioSciences do?: Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
What is PCRX's market cap?: $1.45B, based on the Oct 14 close of $36.40.
What is PCRX's P/E ratio?: 99.2× trailing-twelve-month earnings of $14.64M.
Does Pacira BioSciences pay a dividend?: No regular cash dividend has been paid in the last year.
How much of PCRX is sold short?: 8.1M shares, 21.2% of float, as of Sep 30, 2026.
What sector is PCRX in?: Healthcare, in the Pharmaceuticals industry.

About Pacira BioSciences

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

HQ: Brisbane, CA829 employeesListed Feb 3, 2011pacira.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology